Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
NCT Number: NCT05099198
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Boston, Massachusetts, 02120, United States
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sitagliptin dispensing claim is used as the reference
Glimepiride dispensing claim is used as the reference
Time frame: Through censoring or study completion, up to 765 days after cohort entry
Lab based algorithm: time until failure to maintain metabolic control (HbA1c level >= 7.0% or 53 mmol/mol)
Time frame: Through censoring or study completion, up to 765 day after cohort entry
Claims based algorithm: time until a severe hypoglycemic episode
Time frame: Through censoring or study completion, up to 765 days after cohort entry
Lab based algorithm: HbA1C change from baseline
Brigham and Women's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsNCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial Details